AgeX Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of AgeX Therapeutics generated cash of -$7,800,000, which is less than the previous year. Cash used in financing activities reached the amount of $17,500,000 last year. Net change in cash is therefore -$300,000.
Cash Flow
| 2017 | -6.28M | 5K | 13.27M |
|---|---|---|---|
| 2018 | -7.99M | 1.32M | 6M |
| 2019 | -10.16M | -361K | 6.26M |
| 2020 | -7.81M | -20K | 5.96M |
| 2021 | -7.85M | 666K | 7.24M |
| 2022 | -5.93M | 0 | 6M |
| 2023 | -7.8M | -10M | 17.5M |
AGE Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 645K | 634K | 577K | 2.45M | 6.70M | 7.37M | 259K |
Operating activities | |||||||
Net income | -14.80M | -10.52M | -8.58M | -10.97M | -12.38M | -7.73M | -6.63M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 131K | 132K | 131K | 1.68M | 951K | 535K | 682K |
Stock-based compensation expense | 648K | 760K | 999K | 909K | 1.90M | 1.47M | 752K |
| Deferred income tax benefit | 648K | 760K | 999K | 909K | 1.90M | 1.47M | 752K |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | -607K | 21K | 128K | 10K | -232K | -24K | 0 |
Inventories | -1.15M | 0 | -128K | -10K | 232K | -421K | 0 |
Accounts payable | 1.15M | 144K | -772K | 340K | 169K | 648K | 267K |
Cash generated by operating activities | -7.8M | -5.93M | -7.85M | -7.81M | -10.16M | -7.99M | -6.28M |
Investing activities | |||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | -354K | 0 | 0 |
Investments In Property Plant And Equipment | 0 | 0 | 0 | -20K | -641K | -1.89M | -1K |
Acquisitions Net | 0 | 0 | 466K | 0 | 354K | 3.21M | 0 |
Cash generated by investing activities | -10M | 0 | 666K | -20K | -361K | 1.32M | 5K |
Financing activities | |||||||
Common Stock Issued | 0 | 8K | 496K | 21K | 56K | 0 | 10M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -7M | -15K | 0 | 0 | 0 |
Cash used in financing activities | 17.5M | 6M | 7.24M | 5.96M | 6.26M | 6M | 13.27M |
Net Change In Cash | -300K | 61K | 57K | -1.87M | -4.25M | -668K | 7.11M |
Cash at end of period | 345K | 695K | 634K | 577K | 2.45M | 6.70M | 7.37M |
| Data source | Data source | Data source | Data source | Data source | Data source |